Physician profile
Krishna Urval
NPI 1669582235
$12,246.83
in general payments reported to CMS, 2019-2025
17 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,247 · 2020: $886 · 2021: $669 · 2022: $603 · 2023: $794 · 2024: $699 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480 · Honoraria: $350 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.34 |
| Honoraria | $350.00 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,485.18 | 2019-2025 | Xolair |
| Optinose US, INC. | $3,713.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,036.53 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $960.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $381.60 | 2021-2025 | Tezspire |
| Aimmune Therapeutics, INC. | $377.24 | 2020-2024 | |
| Pfizer INC. | $316.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $211.08 | 2019-2025 | |
| Genzyme Corporation | $193.67 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.51 | 2020-2023 | Hyqvia |
| Kaleo, INC. | $131.73 | 2019-2022 | |
| Shire North American Group INC | $80.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $76.89 | 2020-2021 | |
| Leo Pharma INC. | $39.62 | 2023 | Adbry |
| Csl Behring | $33.07 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.97 | 2020-2023 | Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $19.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Urval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.